C

CSL

Develops and delivers biotherapies and vaccines

Global Procurement Category Lead - Engineering and Construction

Full-Time
No salary listed
Expert
Master's, MBA
Remote in USA
HybridDomestic and international travel required, typically 10–30% domestic and 10–20% international.
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • Minimum 12 years of experience in strategic sourcing, other relevant sourcing experience, or equivalent experience in engineering and construction management.
  • Minimum 2 years of senior leadership experience, preferably with a global team.
  • Minimum 5 years of global team management experience.
  • Strong communication and influencing skills, with the ability to deal with ambiguity and build bridges.
  • Strong understanding of the A&E, EPC, EPCM, CQV, and CSV categories and business.
  • Basic strategic orientation, inquisitiveness, comfort with ambiguity, and self-motivation to identify trends and improvement opportunities aligned with business objectives and strategic plans.
  • Strong executive presence, demonstrated leadership and collaboration skills, and the ability to build effective relationships and influence peers and key stakeholders.
  • Demonstrated ability to organize and lead global teams.
  • Strong project management skills, including planning tasks, assigning resources, managing progress, removing barriers, managing change, resolving conflict, building consensus, and motivating team members across multiple concurrent projects.
  • Strong verbal and written communication skills, including tailoring messages to the audience, presenting information clearly and concisely, applying creative approaches to engage audiences, managing change, resolving conflict, and building consensus.
  • Solid knowledge of category management, strategic sourcing, and supplier relationship management.
  • Ability to build and maintain strong relationships and collaborate effectively with all organizational levels and cross-functionally.
Responsibilities
  • Develop and implement global category strategies for the categories in scope in alignment with corporate and relevant business strategies to establish objectives and action plans that reduce total cost of ownership and risk while increasing innovation, customer service, compliance, and quality.
  • Drive collaboration with the relevant business unit on complex problem resolution, investigative data analytics, process reengineering, and establishment of sustainable programs that meet global needs consistently across affected company areas.
  • Lead and manage key projects involving redesign of global strategy, business models, and ways of working while driving year-over-year financial improvements and operational excellence.
  • Define and implement effective global category management strategies and establish and manage councils for business-critical commodities.
  • Lead key sourcing activities, including negotiations, to reduce cost of ownership and risk and improve quality and supply performance.
  • Lead complex business negotiations with major suppliers and advise on regional sourcing as required.
  • Conduct business with integrity and comply with applicable laws, regulations, and anti-bribery requirements while promoting utilization of small, disadvantaged, and diverse suppliers.
  • Establish and manage supplier relationship management processes according to supplier segmentation and implement supplier risk management strategies in accordance with global policies.
  • Implement global procedures to ensure sourcing activities comply with the CSL Sourcing Policy, Code of Responsible Business Practices, and other compliance standards.
  • Adhere to CSL Supplier Risk Management policies and procedures and use CSL Supplier Risk Management tools as appropriate.
  • Monitor supply performance key performance indicators and conduct regular operational reviews under Procurement governance processes, using supporting analysis and reporting from the Centre of Excellence.
  • Ensure category management roles within the team review and manage supplier performance against agreed standards.
  • Lead, motivate, and develop Procurement employees, including long-term talent development, succession planning, and performance management.
  • Build and maintain professional relationships with senior internal stakeholders and senior external vendor executives to deliver Procurement objectives and manage supplier performance, issues, improvement initiatives, and broader business issues.
  • Lead and participate in global transformation projects and continuous improvement initiatives to deliver targeted benefits.
Desired Qualifications
  • Understanding of the pharmaceutical industry or a related industry.
  • Master's degree in Engineering.
  • Master of Business Administration degree.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.

Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.